Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829976 | 0.80 | LCK (0.40) | HDAC1ACHEBACE1ACP1CHRNA7 | |
| SCHEMBL2475817 | 0.77 | HDAC1 (0.60) | HDAC1ACHEBACE1HDAC3HDAC2 | |
| SCHEMBL2830646 | 0.76 | MAPK1 (0.50) | HDAC1ACHEJAK2HDAC3HDAC2 | |
| SCHEMBL2834235 | 0.75 | AAK1 (0.49) | HDAC1 | |
| SCHEMBL2828988 | 0.75 | MCHR1 (0.48) | HDAC1KDR | |
| SCHEMBL2831485 | 0.73 | NAMPT (0.41) | HDAC1 | |
| SCHEMBL6532661 | 0.72 | CHRNA7 (0.51) | HDAC1ACHECHRNA7KCNH2 | |
| SCHEMBL2828967 | 0.72 | CD274 (0.53) | HDAC1KDRHDAC3HDAC2 | |
| SCHEMBL2832783 | 0.72 | TRPV1 (0.60) | HDAC1ABL1BCRMAPK14 | |
| SCHEMBL2831688 | 0.72 | HDAC1 (0.71) | HDAC1KCNH2MAPK14HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | MKNK1 3525/4885HDAC1 2/4885ACHE 2690/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | MKNK1 3401/4885HDAC1 1/4885ACHE 2041/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | MKNK1 3475/4885HDAC1 2/4885ACHE 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.